Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 779
Rating:

Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK

Dr Charlotte Pawlyn speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston about the transplant eligible pathway of the NCRI Myeloma XI Phase III trial.

Dr Paylwn explains that she was presenting results comparing quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide and dexamethasone) and triplet combination induction therapy in newly diagnosed patients.

Dr Pawlyn reports that the quadruplet therapy induced higher rates of MRD negativity.

Additionally, patients who were MRD negative were found to have improved outcomes when compared with MRD negative patients who were treated with the triplet combination.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

SIOG metastatic renal cell carcinoma


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation